Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 1287128, 8 pages
http://dx.doi.org/10.1155/2016/1287128
Research Article

A Polyethylenimine-Containing and Transferrin-Conjugated Lipid Nanoparticle System for Antisense Oligonucleotide Delivery to AML

Department of Geriatric Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China

Received 5 November 2015; Accepted 27 December 2015

Academic Editor: Xin Ming

Copyright © 2016 Yiming Yuan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Vidal, S. Blagden, G. Attard, and J. De Bono, “Making sense of antisense,” European Journal of Cancer, vol. 41, no. 18, pp. 2812–2818, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. C. A. Stein and Y.-C. Cheng, “Antisense oligonucleotides as therapeutic agents—is the bullet really magical?” Science, vol. 261, no. 5124, pp. 1004–1012, 1993. View at Publisher · View at Google Scholar · View at Scopus
  3. K. T. Flaherty, J. P. Stevenson, and P. J. O'Dwyer, “Antisense therapeutics: lessons from early clinical trials,” Current Opinion in Oncology, vol. 13, no. 6, pp. 499–505, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Juliano, J. Bauman, H. Kang, and X. Ming, “Biological barriers to therapy with antisense and siRNA oligonucleotides,” Molecular Pharmaceutics, vol. 6, no. 3, pp. 686–695, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. Yang, D. Gao, Z. Cao et al., “Drug and gene co-delivery systems for cancer treatment,” Biomaterials Science, vol. 3, no. 7, pp. 1035–1049, 2015. View at Publisher · View at Google Scholar
  6. H. Xu, Z. Li, and J. Si, “Nanocarriers in gene therapy: a review,” Journal of Biomedical Nanotechnology, vol. 10, no. 12, pp. 3483–3507, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Cho, X. Wang, S. Nie, Z. G. Chen, and D. M. Shin, “Therapeutic nanoparticles for drug delivery in cancer,” Clinical Cancer Research, vol. 14, no. 5, pp. 1310–1316, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Chavany, T. Saison-Behmoaras, T. Le Doan, F. Puisieux, P. Couvreur, and C. Hélène, “Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake,” Pharmaceutical Research, vol. 11, no. 9, pp. 1370–1378, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Scheicher, A.-L. Schachner-Nedherer, and A. Zimmer, “Protamine-oligonucleotide-nanoparticles: recent advances in drug delivery and drug targeting,” European Journal of Pharmaceutical Sciences, vol. 75, pp. 54–59, 2015. View at Publisher · View at Google Scholar
  10. A. Jebali, S. M. Kalantar, S. Hekmatimoghaddam, N. Saffarzadeh, M. H. Sheikha, and N. Ghasemi, “Surface modification of tri-calcium phosphate nanoparticles by DOPE and/or anti-E6 antibody to enhance uptake of antisense of E6 mRNA,” Colloids and Surfaces B: Biointerfaces, vol. 126, pp. 297–302, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Ezzat, Y. Aoki, T. Koo et al., “Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides,” Nano Letters, vol. 15, no. 7, pp. 4364–4373, 2015. View at Publisher · View at Google Scholar
  12. J. C. Lai, L. Benimetskaya, R. M. Santella, Q. Wang, P. S. Miller, and C. A. Stein, “G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner,” Molecular Cancer Therapeutics, vol. 2, no. 10, pp. 1031–1043, 2003. View at Google Scholar · View at Scopus
  13. A. W. Tolcher, “Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer,” Seminars in Oncology, vol. 28, no. 4, supplement 15, pp. 67–70, 2001. View at Google Scholar · View at Scopus
  14. S. M. O'Brien, C. C. Cunningham, A. K. Golenkov, A. G. Turkina, S. C. Novick, and K. R. Rai, “Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7697–7702, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. M. Mita, L. Ochoa, E. K. Rowinsky et al., “A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer,” Annals of Oncology, vol. 17, no. 2, pp. 313–321, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. S. L. Moulder, W. F. Symmans, D. J. Booser et al., “Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer,” Clinical Cancer Research, vol. 14, no. 23, pp. 7909–7916, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. P. S. Galatin, R. H. Advani, G. A. Fisher et al., “Phase I trial of oblimersen (Genasense) and gemcitabine in refractory and advanced malignancies,” Investigational New Drugs, vol. 29, no. 5, pp. 971–977, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. P. A. Ott, J. Chang, K. Madden et al., “Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial,” Cancer Chemotherapy and Pharmacology, vol. 71, no. 1, pp. 183–191, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Kircheis, L. Wightman, A. Schreiber et al., “Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application,” Gene Therapy, vol. 8, no. 1, pp. 28–40, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. O. Boussif, F. Lezoualc'h, M. A. Zanta et al., “A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 16, pp. 7297–7301, 1995. View at Publisher · View at Google Scholar · View at Scopus
  21. P. L. Felgner, T. R. Gadek, M. Holm et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 21, pp. 7413–7417, 1987. View at Publisher · View at Google Scholar · View at Scopus
  22. M. L. Forrest, J. T. Koerber, and D. W. Pack, “A degradable polyethylenimine derivative with low toxicity for highly efficient gene delivery,” Bioconjugate Chemistry, vol. 14, no. 5, pp. 934–940, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Fischer, T. Bieber, Y. Li, H.-P. Elsässer, and T. Kissel, “A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity,” Pharmaceutical Research, vol. 16, no. 8, pp. 1273–1279, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Y. Yhee, S. J. Lee, S. Lee et al., “Tumor-targeting transferrin nanoparticles for systemic polymerized siRNA delivery in tumor-bearing mice,” Bioconjugate Chemistry, vol. 24, no. 11, pp. 1850–1860, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. L. B. Jeffs, L. R. Palmer, E. G. Ambegia, C. Giesbrecht, S. Ewanick, and I. MacLachlan, “A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA,” Pharmaceutical Research, vol. 22, no. 3, pp. 362–372, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. T. M. Allen, P. Sapra, and E. Moase, “Use of the post-insertion method for the formation of ligand-coupled liposomes,” Cellular and Molecular Biology Letters, vol. 7, no. 3, pp. 889–894, 2002. View at Google Scholar · View at Scopus
  27. S. Liu, Z. Liu, Z. Xie et al., “Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-κB-dependent DNA methyltransferase activity in acute myeloid leukemia,” Blood, vol. 111, no. 4, pp. 2364–2373, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Yang, Y. Peng, B. Yu et al., “A covalently stabilized lipid-Polycation-DNA (sLPD) vector for antisense oligonucleotide delivery,” Molecular Pharmaceutics, vol. 8, no. 3, pp. 709–715, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. R. J. Klasa, A. M. Gillum, R. E. Klem, and S. R. Frankel, “Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment,” Antisense and Nucleic Acid Drug Development, vol. 12, no. 3, pp. 193–213, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Marcucci, W. Stock, G. Dai et al., “Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3404–3411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. X. Pan, L. Chen, S. Liu, X. Yang, J.-X. Gao, and R. J. Lee, “Antitumor activity of G3139 lipid nanoparticles (LNPs),” Molecular Pharmaceutics, vol. 6, no. 1, pp. 211–220, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. M. S. Muthu, S. A. Kulkarni, J. Xiong, and S.-S. Feng, “Vitamin e TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells,” International Journal of Pharmaceutics, vol. 421, no. 2, pp. 332–340, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Mu and S.-S. Feng, “PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio,” Pharmaceutical Research, vol. 20, no. 11, pp. 1864–1872, 2003. View at Publisher · View at Google Scholar · View at Scopus